GHM Open
Online ISSN : 2436-2956
Print ISSN : 2436-293X
Trends in prostate cancer diagnosis during the COVID-19 crisis: A report from one high-volume Japanese center
Daisuke YamadaTaketo KawaiYusuke SatoYuta YamadaYoshiyuki AkiyamaJimpei MiyakawaSayuri TakahashiHaruki Kume
Author information

2021 Volume 1 Issue 1 Pages 28-30


Self-isolation to prevent the spread of the novel coronavirus SARS-CoV-2 began in April 2020. As a result, the number of prostate needle biopsies taken at our hospital for suspicion of prostate cancer decreased by 30.5%, from 403 in 2019 to 280 in 2020. The number of diagnoses of prostate cancer decreased by 35.4% from 189 to 122. High-risk and intermediate-risk prostate cancers were 36.5% and 49.7%, respectively, in 2019. Assuming that this situation in our hospital reflects events nationwide, approximately 32,575 (high-risk; 11,890, intermediate risk; 16,189) patients annually would be suffering delays in diagnosis. Furthermore, > 90% of the decrease are curable cases in their 60s and 70s, with prostate specific antigen levels of 30 ng/mL or less, with stage T2, and N0M0. Widely aware that more than 30,000 prostate cancers might be overlooked nationwide in 2020, we recommend establishing a health checkup system with infection control and undergoing early testing.

Information related to the author
© 2021 National Center for Global Health and Medicine
Previous article Next article